Early data on Daiichi Sankyo’s Merck-partnered ADC; AstraZeneca’s Dato-Dxd combo; more from Seagen: #ESMO23 roundup

MADRID — Clinical researchers presented data on hundreds of trials over the weekend at the European Society for Medical Oncology Congress here in Spain.

Merck and Daiichi set the tone with their three-ADC deal Thursday night, as many of the big studies over the weekend involved antibody-drug conjugates.

Click here to view original post